Emcure Pharmaceuticals Performance
- Today's Low
- ₹1,677
- Today's High
- ₹1,731
- 52 Week Low
- ₹1,229
- 52 Week High
- ₹1,830
- Open Price₹1,720
- Previous Close₹1,699
- Volume145,703
- 50 DMA₹1,634.85
- 100 DMA₹1,569.04
- 200 DMA₹1,492.80
Emcure Pharmaceuticals Chart
Investment Returns
- Over 1 Month + 5.38%
- Over 3 Month + 18.62%
- Over 6 Month + 23.48%
- Over 1 Year + 22.94%
Smart Investing Starts Here Start SIP with Emcure Pharmaceuticals for Steady Growth!
Emcure Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 35.4
- PEG Ratio
- 1
- Market Cap Cr
- 32,710
- P/B Ratio
- 6.6
- Average True Range
- 59.46
- EPS
- 49.91
- Dividend Yield
- 0.2
- MACD Signal
- 29.29
- RSI
- 56.05
- MFI
- 47.92
Latest Stock News Updates
The rise in profits was attributed to the robust performance in international markets and growth in new launches from Emcure's in-house portfolio
- Business Standard
- 3 weeks 1 day ago
Conference Call with Emcure Pharmaceuticals Management and Analysts on Q4FY26 Performance and Outlook. Listen to the full earnings transcript.
- Trendlyne
- 3 weeks 1 day ago
Pharmaceuticals company Emcure Pharmaceuticals announced Q4FY26 & FY26 results Q4FY26 Financial Highlights: Revenue from operations at Rs 2,470 crore, up 16.7% YoY. EBITDA at Rs 485 crore up 24.5% YoY, EBITDA margins at 19.7%. Reported PAT at Rs 244 crore, up 23.6% YoY. Adj. PAT2 at Rs 279 crore, up by 36.0% YoY. Domestic business sales at Rs 977 crore, up 5.2% YoY. Softer performance largely due to the Zuventus portfolio and team reorganization. International business sales at Rs 1,493 crore, up 25.7% YoY with strong growth across markets supported by base business ramp up and new launches. FY26 Financial Highlights: Revenue from operations at Rs 9,204 crore, up 16.6% YoY, ahead of stated guidance. EBITDA at Rs 1,789 crore up 21.8% YoY, EBITDA margins at 19.4%. Reported PAT at Rs 941 crore, up 33.1% YoY. Adj. PAT2 at Rs 1,008 crore, up by 40.9% YoY. Domestic business sales at Rs 4,027 crore, up 10.0% YoY. Growth in-line with market, led by cardiac, CNS and oncology. Consolidated domestic operations with subsidiary minority stake buyout, strengthened leadership teams across divisions and expanded portfolio via key MNC partnerships. International business sales at Rs 5,177 crore, up 22.2% YoY. Strong momentum from base business growth and new launches from in-house portfolio. Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: "In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over USD 1 billion in revenue and 16.6% growth. International markets demonstrated robust momentum while our domestic business recorded steady growth. We delivered ~41% adjusted PAT growth in the year. We strategically expanded through in-licensing, Zuventus minority buyout and bolt-on acquisitions in the UK and Canada. Our R&D; pipeline in complex injectables and biosimilars remains a key driver of future value. Our priorities remain clear - to deliver sustainable, above-industry growth and consistent margin expansion, while continuing to build sustainable long-term value for all stakeholders.” Result PDF
- Trendlyne
- 3 weeks 1 day ago
Emcure Pharmaceuticals Financials
Emcure Pharmaceuticals Technicals
EMA & SMA
- Bearish Moving Average 1
- Bullish Moving Average 15
- 20 Day
- ₹1,691.89
- 50 Day
- ₹1,634.85
- 100 Day
- ₹1,569.04
- 200 Day
- ₹1,492.80
Resistance and Support
- R3 1,799.37
- R2 1,765.03
- R1 1,745.17
- S1 1,690.97
- S2 1,656.63
- S3 1,636.77
Emcure Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
About Emcure Pharmaceuticals
- NSE Symbol
- EMCURE
- BSE Symbol
- 544210
- Managing Director & CEO
- Mr. Satish Ramanlal Mehta
- ISIN
- INE168P01015
Similar Stocks to Emcure Pharmaceuticals
Popular Stocks
Emcure Pharmaceuticals FAQs
Emcure Pharmaceuticals share price is ₹1,725 As on 28 May, 2026 | 05:08
The Market Cap of Emcure Pharmaceuticals is ₹32709.9 Cr As on 28 May, 2026 | 05:08
The P/E ratio of Emcure Pharmaceuticals is 35.4 As on 28 May, 2026 | 05:08
The PB ratio of Emcure Pharmaceuticals is 6.6 As on 28 May, 2026 | 05:08
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.